| 94.3 27.68 (41.55%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 120.3 |
1-year : | 140.51 |
| Resists | First : | 103 |
Second : | 120.3 |
| Pivot price | 67.7 |
|||
| Supports | First : | 73.74 |
Second : | 55.65 |
| MAs | MA(5) : | 71.48 |
MA(20) : | 66.61 |
| MA(100) : | 53.32 |
MA(250) : | 0 | |
| MACD | MACD : | 3.9 |
Signal : | 2.3 |
| %K %D | K(14,3) : | 70.1 |
D(3) : | 64.1 |
| RSI | RSI(14): 86.8 |
|||
| 52-week | High : | 103 | Low : | 19.44 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KYMR ] has closed above the upper band by 42.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 267.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 103.01 - 103.37 | 103.37 - 103.7 |
| Low: | 85.88 - 86.28 | 86.28 - 86.64 |
| Close: | 93.62 - 94.22 | 94.22 - 94.76 |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Mon, 08 Dec 2025
Kymera Therapeutics announces $500M proposed public offering - MSN
Mon, 08 Dec 2025
Kymera Therapeutics Stock Surge: Time to Buy? - StocksToTrade
Mon, 08 Dec 2025
Kymera Therapeutics (KYMR) Soars 51% on Promising Phase 1b Resul - GuruFocus
Mon, 08 Dec 2025
Kymera Therapeutics (NASDAQ:KYMR) Reaches New 1-Year High - Here's Why - MarketBeat
Mon, 08 Dec 2025
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Early KT-621 STAT6 Trial Data - Yahoo Finance
Mon, 08 Dec 2025
Why Is Kymera Therapeutics Stock Skyrocketing Monday? - Kymera Therapeutics (NASDAQ:KYMR) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 72 (M) |
| Held by Insiders | 4.763e+007 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 8,120 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.2154e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 207.8 % |
| Return on Equity (ttm) | -19.3 % |
| Qtrly Rev. Growth | 4.373e+007 % |
| Gross Profit (p.s.) | -11.35 |
| Sales Per Share | -13.96 |
| EBITDA (p.s.) | -1.134e+008 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -228 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -6.76 |
| Price to Cash Flow | 16.44 |
| Dividend | 0 |
| Forward Dividend | 8.58e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|